Curtis J. Henrich, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 567, Room 219
- Frederick, MD 21702-1201
- henrichcj@mail.nih.gov
RESEARCH SUMMARY
For questions about the Assay Development and Screening Section, please contact Dr. Brice Wilson, Acting Head.
Areas of Expertise
Research
Dr. Henrich was responsible for the coordination of bioassay development, high-throughput screening, and application of assays to natural products isolation within the Molecular Targets Program.
Publications
High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells
Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth
Matching the power of high throughput screening to the chemical diversity of natural products
Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor
Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells
Biography
Curtis J. Henrich, Ph.D.
Dr. Henrich received his Ph.D. in biochemistry from the University of Michigan (thesis research on erythrocyte senescence-related glycoconjugates). He conducted his postdoctoral research in Michigan and at the University of California, San Francisco, which was followed by 14 years in the biotechnology industry (Life Technologies, Inc. and a now defunct start-up called Aptus Pharmaceuticals). He joined the Molecular Targets Program (formerly, Molecular Targets Laboratory) in 2003 first as a Consultant, then as a Senior Scientist affiliated with Leidos Biomedical Research, Inc. (formerly, SAIC-Frederick, Inc.). Dr. Henrich retired in 2024 and is now a special volunteer.
